7.37
price down icon7.18%   -0.57
after-market After Hours: 7.51 0.14 +1.90%
loading
Cadrenal Therapeutics Inc stock is traded at $7.37, with a volume of 86,535. It is down -7.18% in the last 24 hours and down -38.22% over the past month. Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
See More
Previous Close:
$7.94
Open:
$8.07
24h Volume:
86,535
Relative Volume:
2.22
Market Cap:
$17.23M
Revenue:
-
Net Income/Loss:
$-4.85M
P/E Ratio:
-23.77
EPS:
-0.31
Net Cash Flow:
$-3.95M
1W Performance:
-33.00%
1M Performance:
-38.22%
6M Performance:
-44.96%
1Y Performance:
-43.13%
1-Day Range:
Value
$7.1682
$8.07
1-Week Range:
Value
$7.1682
$12.50
52-Week Range:
Value
$7.1682
$22.90

Cadrenal Therapeutics Inc Stock (CVKD) Company Profile

Name
Name
Cadrenal Therapeutics Inc
Name
Phone
904-300-0701
Name
Address
822 A1A NORTH, PONTE VEDRA
Name
Employee
4
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
CVKD's Discussions on Twitter

Compare CVKD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CVKD
Cadrenal Therapeutics Inc
7.37 18.56M 0 -4.85M -3.95M -0.31
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
447.38 114.05B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
748.71 78.80B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
396.04 51.80B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
847.05 53.08B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
166.55 42.33B 447.02M -1.18B -906.14M -6.1812

Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-18-23 Initiated Noble Capital Markets Outperform

Cadrenal Therapeutics Inc Stock (CVKD) Latest News

pulisher
12:59 PM

Is Cadrenal Therapeutics Inc. stock affected by interest rate hikes2025 Major Catalysts & Low Risk High Win Rate Stock Picks - Улправда

12:59 PM
pulisher
Dec 17, 2025

Cadrenal Therapeutics to conduct partnering and investor meetings - marketscreener.com

Dec 17, 2025
pulisher
Dec 17, 2025

Cadrenal Therapeutics To Conduct Partnering And Investor Meetings - TradingView — Track All Markets

Dec 17, 2025
pulisher
Dec 17, 2025

Cadrenal Therapeutics, Inc. Management to Hold Investor and Partner Meetings at the 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative

Dec 17, 2025
pulisher
Dec 17, 2025

Biotech developing new blood thinners meets partners at major health event - Stock Titan

Dec 17, 2025
pulisher
Dec 16, 2025

Cadrenal Therapeutics announces new securities purchase agreement - MSN

Dec 16, 2025
pulisher
Dec 16, 2025

Cadrenal Therapeutics Announces New Securities Purchase Agreement - TipRanks

Dec 16, 2025
pulisher
Dec 14, 2025

Understanding the Setup: (CVKD) and Scalable Risk - news.stocktradersdaily.com

Dec 14, 2025
pulisher
Dec 14, 2025

Cadrenal Therapeutics acquires VLX-1005 from Veralox - MSN

Dec 14, 2025
pulisher
Dec 12, 2025

CVKDCadrenal Therape Latest Stock News & Market Updates - Stock Titan

Dec 12, 2025
pulisher
Dec 12, 2025

Cadrenal's Quiet Expansion Play Is Starting to Get Loud - Voice of Alexandria

Dec 12, 2025
pulisher
Dec 12, 2025

Cadrenal Therapeutics (NASDAQ: CVKD) adds HIT, Factor XIa drugs in quiet expansion - Stock Titan

Dec 12, 2025
pulisher
Dec 12, 2025

Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market - guardonline.com

Dec 12, 2025
pulisher
Dec 12, 2025

Cadrenal Therapeutics (NASDAQ: CVKD) builds multi-asset anticoagulation platform in $40B market - Stock Titan

Dec 12, 2025
pulisher
Dec 12, 2025

Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox By Investing.com - Investing.com Australia

Dec 12, 2025
pulisher
Dec 12, 2025

Cadrenal Therapeutics acquires late-stage drug assets from Maryland biotech - The Business Journals

Dec 12, 2025
pulisher
Dec 11, 2025

Cadrenal Therapeutics acquires VLX-1005 for heparin-induced thrombocytopenia - TipRanks

Dec 11, 2025
pulisher
Dec 11, 2025

Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox - Investing.com

Dec 11, 2025
pulisher
Dec 11, 2025

Cadrenal Therapeutics Acquires VLX-1005 from Veralox - TipRanks

Dec 11, 2025
pulisher
Dec 11, 2025

Cadrenal Therapeutics acquires VLX-1005, a first-in-class Phase 2 12-LOX inhibitor for patients with heparin-induced thrombocytopenia - marketscreener.com

Dec 11, 2025
pulisher
Dec 11, 2025

Cadrenal Therapeutics (Nasdaq: CVKD) adds Phase 2 12-LOX HIT therapy with FDA Fast Track - Stock Titan

Dec 11, 2025
pulisher
Dec 06, 2025

Cadrenal Therapeutics (CVKD) Stock Analysis Report | Financials & Insights - Benzinga

Dec 06, 2025
pulisher
Dec 06, 2025

Aug Gainers: Can Cadrenal Therapeutics Inc stock deliver strong Q4 earnings2025 Sector Review & Daily Momentum Trading Reports - moha.gov.vn

Dec 06, 2025
pulisher
Dec 05, 2025

Is Cadrenal Therapeutics Inc. stock safe for conservative investorsGap Up & Weekly Market Pulse Updates - Newser

Dec 05, 2025
pulisher
Dec 05, 2025

Why Cadrenal Therapeutics Inc. stock attracts global investorsGap Up & Fast Entry Momentum Trade Alerts - Newser

Dec 05, 2025
pulisher
Dec 04, 2025

The Technical Signals Behind (CVKD) That Institutions Follow - news.stocktradersdaily.com

Dec 04, 2025
pulisher
Dec 02, 2025

Can Cadrenal Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Portfolio Summary & Daily Stock Trend Watchlist - Newser

Dec 02, 2025
pulisher
Dec 02, 2025

Cadrenal Therapeutics, Inc. (CVKD) Analyst insights, Price targets and Recommendations - Yahoo Finance UK

Dec 02, 2025
pulisher
Dec 02, 2025

Cadrenal Therapeutics appoints PTC Therapeutics CMO to board By Investing.com - Investing.com Australia

Dec 02, 2025
pulisher
Dec 01, 2025

Cadrenal Therapeutics appoints Dr. Lee Golden to board of directors - marketscreener.com

Dec 01, 2025
pulisher
Dec 01, 2025

Cadrenal Therapeutics Appoints Dr. Golden to Board - TipRanks

Dec 01, 2025
pulisher
Dec 01, 2025

Cadrenal Therapeutics Appoints New Director - TradingView

Dec 01, 2025
pulisher
Dec 01, 2025

Cadrenal Therapeutics, Inc. Appoints Dr. Lee Scott Golden to Board of Directors - Quiver Quantitative

Dec 01, 2025
pulisher
Dec 01, 2025

Cadrenal Therapeutics appoints PTC Therapeutics CMO to board - Investing.com

Dec 01, 2025
pulisher
Dec 01, 2025

Cadrenal Therapeutics, Inc. Appoints Lee Scott Golden, M.D. as Independent Director and Member of Science and Technology Committee - marketscreener.com

Dec 01, 2025
pulisher
Dec 01, 2025

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - Sahm

Dec 01, 2025
pulisher
Nov 28, 2025

Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis - MarketBeat

Nov 28, 2025
pulisher
Nov 27, 2025

Will Cadrenal Therapeutics Inc. stock sustain high P E ratiosWeekly Investment Summary & Smart Allocation Stock Tips - BỘ NỘI VỤ

Nov 27, 2025
pulisher
Nov 22, 2025

Precision Trading with Cadrenal Therapeutics Inc. (CVKD) Risk Zones - news.stocktradersdaily.com

Nov 22, 2025
pulisher
Nov 19, 2025

Why Cadrenal Therapeutics Inc. stock could see breakout soonJuly 2025 Spike Watch & Growth Focused Stock Reports - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Institutional scanner results for Cadrenal Therapeutics Inc.2025 Earnings Impact & Step-by-Step Trade Execution Guides - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Is Cadrenal Therapeutics Inc. stock a good choice for value investors2025 Sector Review & Safe Entry Zone Tips - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award - The Manila Times

Nov 19, 2025
pulisher
Nov 19, 2025

Agilent Technologies (NYSE: A) Debuts Altura Ultra Inert HPLC With 2x Sensitivity - Stock Titan

Nov 19, 2025
pulisher
Nov 19, 2025

Detecting price anomalies in Cadrenal Therapeutics Inc. with AITreasury Yields & Fast Gaining Stock Reports - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

What the charts say about Cadrenal Therapeutics Inc. todayWatch List & Daily Stock Trend Watchlist - newser.com

Nov 19, 2025
pulisher
Nov 18, 2025

Is Cadrenal Therapeutics Inc. stock attractive for retirement portfolios2025 Breakouts & Breakdowns & Risk Managed Investment Entry Signals - newser.com

Nov 18, 2025
pulisher
Nov 18, 2025

Cadrenal Therapeutics Receives Legal Opinion From Blank Rome LLP On ?Validity Of Share Offering - MarketScreener

Nov 18, 2025
pulisher
Nov 18, 2025

Cadrenal Therapeutics Announces New Stock Offering Program - TipRanks

Nov 18, 2025
pulisher
Nov 18, 2025

Cadrenal Therapeutics IncBlank Rome LLP issued legal opinion on $3,438,062 sharesSEC filing - MarketScreener

Nov 18, 2025
pulisher
Nov 18, 2025

[8-K] Cadrenal Therapeutics, Inc. Reports Material Event | CVKD SEC FilingForm 8-K - Stock Titan

Nov 18, 2025

Cadrenal Therapeutics Inc Stock (CVKD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$38.43
price up icon 0.31%
$97.31
price down icon 0.33%
$31.50
price down icon 0.66%
$91.46
price down icon 0.15%
biotechnology ONC
$307.02
price up icon 0.32%
$166.55
price down icon 16.08%
Cap:     |  Volume (24h):